SNCA and Parkinson disease: SNCA is a major risk gene for PD, and gene polymorphisms of SNCA are associated with the common sporadic form of PD.[36] Mouse model was inoculated with α-synuclein preformed fibrils to observe the effect of Cinpanemab on PD.[37,38] Weekly intravenous injection of Cinpanemab resulted in a marked delay in the onset of first paralysis for 7 days and weight loss for 9 days.